Observing Real-World Use of Avacopan in ANCA-Associated Vasculitis
Observes how avacopan is used in people with ANCA-associated vasculitis across Europe.
Plain-language title generated from the registry record
Registry title: Early-access Avacopan in Real-world ANCA-associated Vasculitis
Key facts
- Where
- Leiden, NetherlandsSee the site
Where in Netherlands
- Leiden University Medical CenterLeiden, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Leiden University Medical Center
- Trial code
- NCT06794827
- Record updated
- 27 January 2025
- Original description
The current study proposal aims to investigate the clinical practice variation of the initial use of avacopan for AAV patients in Europe. The study will describe patient characteristics and organ-specific clinical benefit of avacopan treatment in a unique, first-experience cohort of AAV patients. By studying the clinical practice variation of first-experience avacopan treatment, this study will be uniquely positioned to identify pivotal issues on the real-life implementation of avacopan treatment. These observational data can ultimately serve to address current knowledge gaps on avacopan treatment in AAV patients, improve the care and drug-access for AAV patients with avacopan treatment and generate new areas of research.Read full original descriptionShow less
Evaluating Clinical Practice of Early Access Avacopan Treatment for ANCA-associated Vasculitis in European Countries
The current study proposal aims to investigate the clinical practice variation of the initial use of avacopan for AAV patients in Europe. The study will describe patient characteristics and organ-specific clinical benefit of avacopan treatment in a unique, first-experience cohort of AAV patients. By studying the clinical practice variation of first-experience avacopan treatment, this study will be uniquely positioned to identify pivotal issues on the real-life implementation of avacopan treatment. These observational data can ultimately serve to address current knowledge gaps on avacopan treatment in AAV patients, improve the care and drug-access for AAV patients with avacopan treatment and generate new areas of research.
Inclusion: Established diagnosis of GPA or MPA; Treatment (initiation) with avacopan; Informed consent for use of medical data.
Exclusion: If there is no AAV disease activity present that can be supported by an objectifiable clinical measure or assessment; If a subject is below 16 years old.